Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Daré Bioscience has one FDA-approved product—XACIATO™ (clindamycin phosphate vaginal gel) for bacterial vaginosis—and a broad pipeline targeting women’s health needs in contraception, sexual health, menopause, and fertility. Its lead programs include Ovaprene® (a hormone-free monthly contraceptive ring), Sildenafil Cream for female sexual arousal disorder, DARE-HRT1 intravaginal ring for menopausal hormone therapy, and the DARE-LARC1 long-term implantable drug/device platform. The company partners with major pharma companies like Bayer and Organon to commercialize its products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DaRev.